For the aging populations of Europe, many emerging health problems in addition to myocardial infarction and stroke are associated with hypertension. Recently, the role of hypertension in the risk of vascular cognitive impairment and dementia has been highlighted, and there are studies to show that control of hypertension may slow this process. Furthermore, as many elderly individuals will also develop type 2 diabetes or impaired renal function, the risk of hypertension in these patients is more pronounced. New guidelines have tried to provide evidence-based treatment algorithms in which control of hypertension is just one aspect of general risk factor control, with the aim of decreasing the total risk.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Papers of particular interest, published recently, have been highlighted as:• Of importance •• Of major importance
• Driver JA, Djoussé L, Logroscino G, et al.: Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study. BMJ 2008, 337:a2467. This is an important epidemiologic observational study of morbidity and mortality in the oldest old.
Molander L, Lövheim H, Norman T, et al.: Lower systolic blood pressure is associated with greater mortality in people aged 85 and older. J Am Geriatr Soc 2008, 56:1853–1859.
Vasan RS, Beiser A, Seshadri S, et al.: Residual lifetime risk for developing hypertension in middle-aged women and men. The Framingham Heart Study. JAMA 2002, 287:1003–1010.
Coope J, Warrender TS: Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986, 293:1145–1150.
Amery A, Brixko R, Clement D: Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet 1985, 328:589–592.
Prevention of stroke by antihypertensive drug treatment in older patients with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. JAMA 1991, 265:3255–3264.
Staessen JA, Fagard R, Thijs L, et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997, 350:757–764.
Dahlof B, Lindholm LH, Hansson L, et al.: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991, 338:1281–1285.
Medical Research Council Trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992, 304:405–412.
Musini VM, Tejani AM, Bassett K, Wright JM: Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev 2009, (4):CD000028.
PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001, 358:1033–1041.
Rodgers A, Chapman N, Woodward M, et al.: Perindopril-based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. J Hypertens 2004, 22:653–659.
Gueyffier F, Bulpitt C, Boissel JP, et al.: Antihypertensive drugs in very old people: a subgroup meta-analysis of randomized controlled trials. Lancet 1999, 353:793–796.
•• Beckett NS, Peters R, Fletcher AE, et al; HYVET Study Group: Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008, 358:1887–1898. This is the first and only randomized controlled trial investigating the effect of antihypertensive treatment on morbidity and mortality in patients more than 80 years of age.
• Peters R, Beckett N, Forette F, et al.: Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind placebo controlled trial. Lancet Neurol 2008, 7:683–689. This study showed that antihypertensive therapy prescribed to old patients does not increase the risk for dementia.
Messerli FH, Grossman E, Goldbourt U: Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998, 279:1903–1907.
Khan N, McAlister FA: Re-examining the efficacy of β-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006, 174:1737–1742.
Mancia G, de Backer G, Dominiczak A, et al.: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105–1187.
Mancia G, Laurent S, Agabiti-Rosei E, et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009 Oct 15 (Epub ahead of print).
• Butt TF, Branch RL, Beesley L, Martin U: Managing hypertension in the very elderly: Effect of adverse drug reactions (ADRs) on achieving targets. J Hum Hypertens. 2010, 24:514–518. This article describes obstacles (such as problems related to adverse drug effects and interactions) in applying hypertension guidelines in old patients.
No potential conflicts of interest relevant to this article were reported.
About this article
Cite this article
Carlberg, B., Nilsson, P.M. Hypertension in the Elderly: What Is the Goal Blood Pressure Target and How Can This Be Attained?. Curr Hypertens Rep 12, 331–334 (2010). https://doi.org/10.1007/s11906-010-0138-y
- Blood Pressure